Stockreport

HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

HUTCHMED (China) Limited - American Depositary Shares  (HCM) 
NASDAQ:AMEX Investor Relations: chi-med.com/investors/information-for-shareholders
PDF HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that [Read more]